

NZX APPENDIX 1 RELEASE

This document relates to Pacific Edge Limited's ("the Company") financial results for the year ended 31 March 2017, released to NZX on 24 May 2017.

The results have been audited.



PACIFIC EDGE LTD
CANCER DIAGNOSTICS COMPANY

RESULTS FOR ANNOUNCEMENT TO THE MARKET FOR THE YEAR ENDED 31 MARCH 2017

REPORTING PERIOD: YEAR ENDED 31 MARCH 2017

PREVIOUS REPORTING PERIOD: YEAR ENDED 31 MARCH 2016

			AMOUNT (\$000)	PERCENTAGE CHANGE
Revenue from ordinary activities, made up of: (\$000)				
- Product Sales and Licence Fees	8,062	62% Increase	9,167	44% Increase
- Grants Received and Research Rebates	1,105	21% Decrease		
Profit (loss) from ordinary activities after tax attributable to security holder			(20,980)	34% Increase
Net profit (loss) attributable to security holders			(20,980)	34% Increase

INTERIM/FINAL DIVIDEND

The Company does not propose to pay dividends to shareholders.

NET TANGIBLE ASSETS

Net tangible assets per share is 5.1 cents per share at 31 March 2017 (31 March 2016: 7.9 cents per share).

COMMENTARY ON RESULTS

For commentary on the results please refer to the commentary on the related NZX release.

FINANCIAL INFORMATION

The Appendix 1 Release should be read in conjunction with the audited Financial Statements for the year ended 31 March 2017 which have been released together with this NZX Appendix 1 Release.

FULL YEAR RESULTS ANNOUNCEMENT

FOR THE YEAR ENDED 31 MARCH 2017

The information below is as required by Appendix 1 of the NZX Main Board Listing Rules.

1.1 DETAILS OF THE REPORTING PERIOD AND THE PREVIOUS REPORTING PERIOD

The reporting period is for the year ended 31 March 2017 ('current year') with the comparative period being for the year ended 31 March 2016 ('previous year').

1.2 INFORMATION PRESCRIBED BY NZX

Refer to "Results for Announcement to the Market".

1.3 THE FOLLOWING INFORMATION:

(a) A Statement of Financial Performance

Refer to the Financial Statements for the year ended 31 March 2017.

(b) A Statement of Financial Position

Refer to the Financial Statements for the year ended 31 March 2017.

(c) A Statement of Cash Flows

Refer to the Financial Statements for the year ended 31 March 2017.

(d) Details of dividends or distributions and dividend or distribution payments

The Company does not propose to pay dividends to shareholders.

(e) Details of any dividend or distribution reinvestment plans in operation and the last date for the receipt of an election notice for participation in any dividend or distribution reinvestment plan

The Company has no dividend reinvestment plan.

(f) A Statement of Movements in Equity

Refer to the Financial Statements for the year ended 31 March 2017.

(g) Net tangible assets per security

Refer to the Results for Announcement to Market.

(h) Details of entities over which control has been gained or lost during the period

Entities over which control has been lost Nil

Entities over which control has been gained Nil

(i) Details of associates and joint ventures

Nil

(j) Any other significant information

Nil

(k) Commentary on result

For commentary on the result please refer to the commentary in the related NZX release.

FULL YEAR RESULTS ANNOUNCEMENT

FOR THE YEAR ENDED 31 MARCH 2017

(l) Audited Financial Statements

The Financial Statements for the year ended 31 March 2017 have been audited. Please refer to the audit report contained in the Financial Statements for the year ended 31 March 2017.

(m) Any major changes or trends in the business

Refer to the commentary in the related NZX release.

(n) Unrealised Gains

There are no unrealised gains resulting from the revaluation of assets of the Company or its subsidiaries, or any unrealised net changes in values or development margins of investment assets included as separate items after profit before extraordinary items.

3.1 BASIS OF PREPARATION

These financial statements have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with New Zealand equivalents to International Financial Reporting Standards (NZIFRS) and other applicable New Zealand Financial Reporting Standards, as appropriate for profit-oriented entities. They also comply with International Financial Reporting Standards.

3.2 ACCOUNTING POLICIES

Refer to Statement of Accounting Policies in the Financial Statements for the year ended 31 March 2017.

3.3 CHANGES IN ACCOUNTING POLICIES

There have not been any accounting policy changes during the year ended 31 March 2017.

3.4 AUDIT REPORT

The Financial Statements for the year ended 31 March 2017 have been audited and include an audit report.

3.5 ADDITIONAL INFORMATION

Not applicable.

The Financial Statements were approved by the Board of Directors on 24 May 2017.



Chris Gallaher
Chairman



PACIFIC EDGE LTD
CANCER DIAGNOSTICS COMPANY

87 St David Street, PO Box 56, Dunedin, New Zealand
P +64 3 479 5800 F +64 3 479 5801
www.pacifedge.co.nz